Therapeutic inhibition of PPAR alpha-HIF1 alpha-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia
Hui Zhou,Yuelong Jiang,Yuetin Huang,Mengya Zhong,Dongmei Qin,Chendi Xie,Guangchao Pan,Jinshui Tan,Manman Deng,Haijun Zhao,Yong Zhou,Yuanfang Tang,Qian Lai,Zhihong Fang,Yiming Luo,Yirong Jiang,Bing Xu,Jie Zha
DOI: https://doi.org/10.1016/j.canlet.2022.215997
IF: 9.756
2023-01-01
Cancer Letters
Abstract:Treatment of acute myeloid leukemia (AML) with chemotherapeutic agents fails to eliminate leukemia stem cells (LSC),and thus patients remain at high risk for relapse. Therefore, the identification of agents that target LSC is an important consideration for the development of new therapies. Enhanced glycolysis in LSC contributes to the aggressiveness of AML, which is difficult to be targeted. In this study, we showed that targeting peroxisome-proliferator-activated receptor alpha (PPAR alpha), a ligand-activated transcription factor by chiglitazar provided a promising therapeutic approach. We first identified that chiglitazar reduced cell viability and proliferation of the leukemia stem-like cells population in AML. Treatment with chiglitazar blocked the ubiquitination of PPAR alpha and increased its expression, resulting in the inhibition of glucose metabolism and apoptosis of AML cells. Consistent with its anti-leukemia stem-like cells activity in vitro, chiglitazar treatment in vivo resulted in the significant killing of leukemia stem-like cells as demonstrated in AML patient-derived xenograft (PDX) models. Mechanis-tically, PPAR alpha overexpression inhibited the expression and promoter activity of PGK1 through blocking HIF1-alpha interaction on the PGK1 promoter. Thus, we concluded that targeting PPAR alpha may serve as a novel approach for enhancing stem and progenitor cells elimination in AML.